Terapêutica anti-retroviral na infecção a VIH (2ª parte)

Autores

  • Eugénio Teófilo Interno do Internato Complementar de Medicina Interna, Serviço 3 do Hospital de Santo António dos Capuchos

Palavras-chave:

.

Resumo

.

Downloads

Não há dados estatísticos.

Referências

Gaynor R. Cellular transcription factors involved in the regulati­ on ofVIH-1 gene expression. AIDS 1992;6:347-364.

Hsu M-C et ail. Inhibition of HIV replication in acute and chronic infection in vitro by a TAT antagonist. Science 1991; 213 :1-3

Bragman Keith. Tat Antagonist; Personal Comunication. AIDS and Medication: 3rd European Meeting on: Triais, Drugs and Medication. Berlin 1993

Kempf D. HIV protease as a therapeutic agent. PAACnotes 1993;April: 143-145

Lambert DM et ai. Human immunodeficiency virus type 1 prote­ase inhibitors irreverssily block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemothera 1992;36(5):982-988

Tyagi SC. Inhibitors os human immunodeficiency virus type 1 protease. Biochem Cellbiol 1992;70(5):309-315

Martin JA. Recent advances in the design of HIV proteinase inhi­bitors. Antiviral Res 1992;17(4):265-278

Graves BJ et al. The three-dimensionat x-ray crystal structure of HIV- 1 protease complexed with a hydroxyethylene inhibitor. Adv Exp Med Biol 1991;306:455-460

Schram HJ et al. Inhibition of HIV- 1 protease by short peptides derived from the terminal segments ofthe protease. Bioch bi­ophys Res Commun 1992;184(2):980-985

Debouck C. The HIV-1 proteases a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992;8(2): 153-164.

Wainberg M. New Anti-virais. Comunicação oral 1 1.1, 2nd Inter­ national Congress on Drug Therapy in HIV Infection, Novem­ bro 1994.

HIV protease inhibitors, AIDS Therapies 1992:1-13

Robins T, Plàttner J. HIV Protease inhibitors: their anti-HIV acti­ vity and potential roleintreatment. J AIDS 1993;6:172

DeNoon DJ. US Trial of protease inhibitor set to beguin. AIDS Weekly 1992; Nov 16:3

Otto MJ et al. ln vitro isolation and identification of human im­ munodeficiency virus (HIV) variants with reduced sensivity to C-2 simmetrical inhibitors of HIV type I protease. Proc Nat Acad Svi USA 1993;90(16):7543-7547

El-Farrash M, Kuroda M, Harada S. HIV-1 Mutation to Escape the Effect of Protease Inhibitors in vitro Impaired its Infectivi­ty and Cytopathogenicity. Poster 6, 2nd International Congress on Drug Therapy in HIV Infection, Novembro 1994.

Moyle G. Proteinase Inhibityors. ln: Resistance to Antiretroviral Compounds. Ed: Mediscript 1994.

Boucher C, Larder B. Resistance to Protease Inhibitors. ln: Viral Variation and Therapeufjc Stratagies in HIV Infection. Ed: Meditech Media 1994.

Barry D. Tripie Combinations anel Future Research Directions. AIDS Care 1994; 1: 28-31.

Chang H. Highlights From the Third International HIV Drug Resistance Workshop. AIDS Care 1994;1: 32-35.

National Institute of Allergy and Infectious Diseases: ACTG 229 Executive Summary: Antiviral Trial of Combination Therapy. Maio 1994.

GMHC Treatment Issues. Protease Inhibitors: overview anel analysis 1994;8(2):1-8

Roberts NA. HIV proteinase inhibitor Ro 31-8959: un updadte on its biological properties. 1992 ICAAC symposium abstract

Bragman K. Personal communication: AIDS and Medication: 3rd European Meeting on: Triais, Drugs and Medication. Ber­lin 1993

Kitchen V, Skinner C, Lane E, et ai. Long Term Follow-up of the Phase 1/11 Study of Saquinavir, in Asymptomatic or Mildly Symptomatic HIV Infection. Comunicação oral 11.3, 2nd In­ternational Congress on Drug Therapy in HIV lnfection No­vembro 1994.

Ives K, Galpin S, Foxall R, et ai. Resistance to Saquinavir (Ro3 1- 8959) Occurs During Patient Treatment. Poster 1, 2nd Interna­tional Congress on Drug Therapy in HIV Infection. Novem­ bro 1994.

Duncan I, Jacobsen H, Hanggi M, et ai. Genotypic Characteri­ zation ofHIV- 1 form Patients after Prolonged Treatment With the Proteinase Inhibitor Saquinavir. Poster 5, 2nd Internatio­ nal Congress on Drug Therapy in HIV Infection. Novembro 1994.

Massimo A, Ercoli L, Sarmati L, et ai. Characterization of HIV Drug Sensivity during Antiretroviral treatment With a Protei­nase Inhibitor (Ro-3 1-8959 - Saquinavir) Alone or in Combi­ nation With Zidovudine. Comunicação oral 5. 7, 2nd Interna­tional Congress on Drug Therapy in HIV Infection. Novem­bro 1994.

Johnson V. Combination Therapy: More Effective Control of HIV Type 1?. AIDS Res Hum Retrov 1994; 10: 907-912.

Emini E, Deutsch P, Schleif W, et al. Clinical Development of HIV-1 Resistance to the Virai Protease Inhibitor L-735,524. Comunicação oral 11.5, 2nd Intemational Congress on Drug Therapy in HIV Infection. Novembro 1994.

Danner S, Cooper D, Gudiol F, et al. Safety, Pharmacokinetics and Virological/Immunological Efficacy of ABT-538, a HIV­ Protease Inhibitor. A Randomised, Placebo Controlled Phase I/II Study. Comunicação oral 11.2, 2nd International Congress on Drug Therapy in HIV Infection. Novembro 1994.

Wins]ow D, Mayers D, Scarnati H, et al. ln vitro Susceptibility of Clinical Isolates of HIV-1 toXM323, aNon-PeptidylHIVProtea­ selnhibitor. AIDS 1994; 8: 753-756.

LipfordJ, Worland ST, Farret CM, et al. Nucleotide Binding by the HIV-1 Integrase Protein in vitro. J AIDS 1994; 7: 1215-1223.

Fischl M, Resnick L, Coombs R, et al. The safety and Efficacy of Combination N- Butyl-Deoxyrojimycin (SC-48334) and ZDV in Patients with HIV Infection anel 200- 500 CD4 mm3. J AIDS 1994; 7: 139-147.

Austin J, Wood K. Cytokines Mediating Inflammatory anel Effec­ tor Fnnctions. ln: Principies of Cellular and Molecular lmmu­nology; 1993: 572-578. Ed: Oxford University Press.

Kurz, Fujinami. Immune response to viral infection in Vírus anel Bone Marrow. 1994

Walker RE, Lane HC. Interferon-a in HIV Infection in de Vita ed AIDS: etiology, Diagnosis, Treatment and Prevention 1992, JB Lippincott.

Lane HC et ai. Interferon-a in patients with asymptomatic hu­ man immunodeficiency virus (HIV) infection. Ann lnt Med 1990; 112(11):805-811

Krown SE. Interferon anel other biologic agents for the treat­ ment of Kaposi's Sarcoma. Hematology/Oncology Clin Nor A­mer 1991; 5(2): 311-322.

Ho DD et ai. Recombinant interferon alfa-A supresses HTLV-III replication in vitro. Lancet 1985; 1: 602-604.

Buimovivi-Klein E, Lange M, Klein RJ et al. Long-term follow­ up of serum-interferon and its acid stability in a group of homosexual men. AIDS Res 1986; 2: 99.

Preble OT, Rook AH, Steis R et al. lnterferon-induced 2',5'-oli­ doadenylate synthetase during interferon alpha therapy in homosexual men with Kaposi's sarcoma. Marked deficiency in biochemical response in patients with the acquired immu­nodeficiency syndrome.J Inf Dis 1985; 152: 457.

Edlin BR et al. In-vitro resistance to zidovudine and alpha-inter­feron in HIV isolates from patients: Correlations with treatment duration and response. Ann. lnt. Med 1992; 117: 437-460.

Poli G, Orenstein JM, Kinteret et al. Interferon-alpha but not AZT supresses HIV expression in chronically infected cell lines. Science 1989; 244: 575.

Spiegel RJ. The alpha-interferons: Clinical overview. Semin Oncol 1987; 14 (suppl 2): 1.

Brockmeyer NH, Keller A, Seemann U et al. Two Year Double­ blind Randomized Triai of Zidovudine Alone or in Combina­tion with Low Dose Interferon- Alpha or lnterferon-Beta; re­ sumo P248 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milão. Março 94

Kaiser G, Jaeger H, Birkmann J, Poppinger J et al. Low-dose oral natural interferon-a in 29 patients with HIV infection: a double-blind, randomized, placebo- controlled triai. AIDS 1992; 6: 563-569.

de-Gorgolas M, Castrillo JM, Fernadez-Guerrero ML et al. Vis­ceral Leishmaniasis in patients with AIDS: report of three ca­ses treated with INF gamma. Clin Inf Ois 1993;17(1):56-58

McMahon DK et al. A phase I study of subcutaneous recombi­ant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994; 8: 59-66.

Wood R, Montoya JG, Kundu SK et ai. Safety and efficacy of poltethyleneglycol-modified interleukin -2 and zidovudine in human immunodeficiency virus type 1 infection: a case 1/11 study. J Inf Ois 1993; 167(3): 519-525.

Kovacs J, Baseler M, Dewar R, et al. lncreases in CD4 T Iym­phocytes with Intermittent Courses of Interleukin-2 in Pati­ents with Human Immunodeficiency Virus Infection. N Engl J Med 1995; 332: 567-575.

Klimas N, Patarca R, WallingJ, et ai. Clinical and Immunologi­cal Changes in AIDS Patients following Adoptive Therapy with Activated Autologous CDS T-Cells and lnterleukin-2 Infusi­on. AIDS 1994; 8: 1073-1082.

Lahdevirta J, Maury CPJ, Teppo AM et ai. Elevated leveis of circulating cachectin/tumor necrosis factor in patients with the acquired immunodeficiency syndrome. Am J Med 1988; 85: 289-291.

Dezube BJ, Pardee AB, Chapman B et ai. Pentoxyphylline (Tren­tal) decreases tumolr necrosis factor (TNF) and HIV replicati­on in patients with AIDS. VII International Conference on AIDS, Amsterdam 1992 (Abstract MoB0019).

Johnston MI, Hoth DF. Presem status and future prospects for HIV therapies. Science 1993; 260: 1286-1293.

Mitsuyasu R. Cytokine Therapies for HIV Infection. Comunica­ ção oral 16.1. 2nd lnternational Congress on Drug Therapy in HIV Infection. Novembro 1994.

Goldstein D, tomkinson E, Couldwell D, et al. Phase I AIB Trial, of Imiquimod, an Oral Interferon Inducer in Asymptomatic HIV Positive Individuais. Comunicação oral 16.2, 2nd lnter­ national Congress on Drug Therapy in HIV Infection, Novem­ bro 1994.

Bridges S, Sarver N. Gene Therapy and Immune Restoration for HIV Disease. Lancet 1995; 345: 427-432.

. Rhodes A, James W. lnhibition of heterologous strains of HIV by antisense RNA. AIDS 1991; 5: 145-152.

Boyd MT, Schulz TF. Antisense RNA to treat HIV infections. AIDS 1991; 5: 225-226

Sereni D, Katlama C, Gouyette A, et al. Phase I Study of Single Intravenous and Subcutaneous Ascending Doses of GEM 91 in HIV Positive Asymptomatic Volunteers. Poster 57, 2nd ln­ ternational Congress on Drug Therapy in HIV Infection. No­ vembro 1994.

Echetebu C, Rhim H, Herrmann C, et ai. Construction and Cha­racterization of a Potent HIV-2 Tat Transdominant Mutant Pro­tein. J AIDS 1994; 7: 655-664.

Van LuzenJ, SchmitzJ, Dewgler K, et al. High Yields of CD4+ and CDS+ T- Lymphocytes can be Obtained by Lymphaphe­ resis an ex vivo Propagation for Autologous Adoptive Immu­notherapy of HIV Infection. Poster 44, 2nd Internacional Con­gress on Drug Therapy in HIV Infection. Novembro 1994.

Van LunzenJ, Schmitz T, Dengler K, et al. High Yelds of CD4+ and CDS+ T- Lymphocytes Can Be Obtained by Lymphaphe­ resis and Ex vivo Propagation for Autologous Adoptive Imr­ nunotherapy of HIV-Infection; resumo 048 - 4th European Conference on Clinical Aspects and Treatment of HIV lnfecti­ on, Milão. Março 1994.

Sandstrom E. Therapeutic Vaccines. Comunicação oral 15.2, 2nd International Congress on Drug Therapy in HIV Infection, Novembro 1994.

Birx D, Redfield R. Therapeutic HIV Vaccines: Concept, Cur­ rent Status, and Future Directions. ln: Textbook of AIDS Me­ dicine; 1994: 693-71 1. Ed.-Williams & Wilkin.

Lederman M. Host-Directed and Immune-Based Therapies for Human Immunodeficiency Virus Infection. Ann lntern Med 1994; 121: 218-222.

Wahren B, Persson C, Levi M, et al. Changing T-Cell Immunity in HIV. Vaccination. Comunicação oral 15.3, 2nd Internatio­nal Congress on Drug Therapy in HIV Infection. Novembro 1994.

Girard MP, Shearer GM. Vaccines and immunology: Overview. AIDS 1993; 7(sup.1): Sl15-Sl16.

Clerici M. Cell mediated immunity in HIV infection. AIDS 1993; 7(sup. 1): S135- S140.

Fast PE, Walker MC. Human trials of experimental AIDS vacci­nes. AIDS 1993; 7(sup. l): S147-S160.

Sneller MC, lmmunologic approaches to the therapy of HIV- 1 infection. Ann NY Acad Science 1993; 685: 687-696.

Adams SE, Paoletti E. Use of new vectors for the development of vaccines. AIDS 1993; 7(sup O: S141-Sl46.

Haynes BF. Scientific and social issues of human immunodefici­ency virus vaccine development. Science 1993; 260: 1279-1286.

Wahren B, Bratt G, Rensson C, et al. Improved Cell-Mediated Immune Responses in HIV-1 lnfected Asymptomatic Indivi­duals after Immunization With Envelope Glycoprotein gpl60. J AIDS 1994; 7: 220-229.

Peters B, Cheingsong-Popov R, donegan D, et al. A Pilot Phase II Study of the Tolerance and Safety of HIV pl7/p24:Ty-VLP ((p24-VLP) in Asymptomatic HIV Seropositive Subjects. Co­municação oral 15.4, 2nd Internacional Congress on Drug Therapy in HIV Infection. Novembro 1994.

Bratt G, Ericksson L, Sandstrom E et al. A 25 Months repor!on a Study of GP160 Vaccine in Asymtpomatic HIV Carriers; resu­mo P308 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milão - Março 94

Biselli R, Loomis L, Bono V, et al. Immunization of HIV-1 Infec­ted Patients with RGP160: Modulation of Anti-RGP120 Anti­ body Spectrotype. J AIDS 1994; 7: 1016- 1024

Pontesilli O, Alario C, Carlesimo M et al. lmmunological As­ sessment of Recipients of Immunotherapy with Recombinam GP160, in Association or not with AZT; resumo P310 - 4th European Conference on Clinical Aspects and Treatment of HIV lnfection, Milão - Março 94

Sutor GC, Lang S, Jurkiewicz E et al. Anti-CD4 Idiotype Vacci­nation in Early stage HIV Disease; resumo 049 - 4th European Conference on Clinical Aspects and Treatment of HIV Infecti­on, Milão - Março 94

Sutor G-C, Lang S, Jurkiewics E, et al. Anti-CD4 Idiotype Vacci­nation in HIV Disease. Poster 115, 2nd International Congress on Drug Therapy in HIV Infection, Novembro 1994.

Ziegner U, Peters G, Jolly D, et al. Cytotoxic T-Lymphocyte ln­ duction in HIV-1 Infected Asymptomatic Patients Immunized with Retrovector-transduced Autologous Fibroblasts Expres­sing HIV-IIIIB Env/rev Proteins. AIDS 1995; 9: 43-50.

Sarobe P, Lasarte J, Golvano J, et al. lnduction of Neutralizing Antibodies Agains Human Immunodeficiency Virus Type 1 Using Synthetic Peptide Constructs Containing an Immuno­ dominant T-Helper Cell Determinant from vpr. J AIDS 1994; 7 835-840.

Cooper D. Clinicai implications of combination therapy. Perso­ nal communication at Aspects of Antivirai Combination The­ rapy in HIV Management; Mar 1993: Vienna

Fidclian AP. Future Combinations Regimens. Personal commu­nication at Aspects of Antiviral Combination Therapy in HIV Management; Mar 1993: Vienna

Sande M. Wich Antiviral and When?. Comunicação oral 3 .1 , 2nd International Congress on Drug Therapy in HIV Infecti­on. Novembro 1994.

Fischl M. Efficacy anel Toxicities of Combination Antiretroviral Therapies. Comunicação oral 7.2, 2nd lntemational Congress on Drug Therapy in HIV lnfection, Novembro 1994.

Harrigan P, Kemp S, Kinghom I, et al. A Placebo Controlled Triai of AZT Alone or in Combination With ddl or ddC: Virai Load and Drug Resistance. Poster 7, 2nd Intemational Con­gress on Drug Therapy in HIV lnfection. Novembro 1994.

Montaner. Julio S. Srour L, et al. The Short-Temm Safety and laboratory Marker Effect of ZDV+ddl vs. ZDV+ddC in Sub­ jects ,vith CD..J Cells 50-350/,uL. A Ranclomisecl Comparative Triai with an Open Arm. Poster 24. 2nd Intemational Con­ gress on Drug Therapy in HIV Infection. Novembro 1994.

Wainberg M. MontanerJ Rachlis A. et al. Long Temm Follow­ up of a Double 13lincl Stucly of cldl versus Continuecl AZT Among Individuais with CD4s 200- 500/mm'. Poster 25. 2nd lntemational Congress on Drug Therapv in HIV Infection, Novembro 1994.

Mauss S, Armbrecht C, Adams O, et al. Efficacy anel Tolerance of dcl!+ZDv versus clclC+ZDV in Patients with Rapicl Progres­ sion of HIV Infection uncler treatment with ZDV. Poster 27, 2nd lntemational Congress on Drug Therapy in HIV Infecti­ cm, Novembro 1994.

Gensollen S. Mars M, Bongrancl M, et ai. A Comparative Triai Between AZT+dei! and Maintenance of AZT or deli in HIV In­ fectecl Patients. Poster 28, 2nd Intemational Conress on Drug Therapy in HIV Infection, Novembro 1994.

National Institute of Allergy anel Infectious Diseases: ACTG 155, Executive Summary: The Effectivness of AZT Alone, ddC Alo­ ne or AZT/dclC Combination Is Similar Overall for Patients with HIV Aclvancecl Disease, Junho 1993.

Fischl M, Stanley K, Collier A, et al. Combination anel Monothe­rapy with Ziclovudine anel Zalcitabine in Patients with Advan­ ed HIV Disease. Ann Int Meel 1995; 122: 24-32.

Skowron G, Bozzette SA, Lim Letal. Alternating and intermit­ tent regimens of ziclovucline anel elideoxycytieline in patients with AIDS or AIDS-related complex. Ann IntMecl. 1993:118:321-1330.

Yarchoan R et al. A randomizecl pilot stucly of alternating or simultaneous ziclovueline anel eliclanosine therapy in patients with symptomatic human immunodeficiency virus infection. J lnfec Dis, 1994;169:9-17.

Graham N, Saah J, Park L, Multicenter AIDS Cohort Study (MACS). Survival in ZDV-Experirenced Patients: Combination Antiretroviral Therapy Vs. clcll/elelC Monotherapy Vs. Con­ tinuecl ZDV Monotherapy. Comunicação oral 7.4, 2nd Inter­ national Conress on Drug Therapy in HIV Infection, Novem­ bro 1994.

Spruance SL, Pavia AT, Peterson D et al. Didanosine compareci with continuation of zidovudine in HIV-infected patients with signs of clinicai deterioration while receiving zidovudine. Ann lnt Med. 1994; 120: 360-368.

Kahn JO, Lagakos SW, Richman DO et al. A controllecl triai com­ paring continuecl ziclovudine with eliclanosine in human immunocleficiency virus infection. N Engl J Mecl 1992; 327: 581- 587.

Collier AC et al. Combination therapy with ziclovudine anel eli­ danosine compared with ziclovudine alone in HIV-1 infecti­ on. Ann.lnt. Med. 1993; 119: 786-793.

Fischl MA, Olson RM, Follansbe SE et al. Zalcitabine compareci with zidovucline in patients with aclvanced HIV-1 infection who received previous ziclovucline therapy. Ann Int Mecl 1993: 118: 762-769.

Meng TC et al. Combination therapy with zidovudine and dicleoxycyticline in patients with aclvancecl human immunode­ ficiency vírus infection. Ann Int Mecl 1992; 116: 13-20.

Schooley R and The Wellcome Resistance Stucly Collaborative Group. Trial ofZDV/DDIVS ZDV/DDCVS ZDV in HIV lnfec­ted Patients With CD4 Cell Counts Less Than 300: Preliminary Results; resumo 052 - 4th European Conference on Clinical Aspects and Treatment of HIV lnfection, Milão. Março 1994.

Mauss S, armbrecht C, Adams O et al. Combination Therapy DDI + ZDV VS. DDC + ZDV in Patients With Rapid Progressi­on of HIV Infection Uncler Treatment With ZDV: resumo 038- 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Milão. Março 1994.

Désormeaux A. Harvie P, Perron S. et al. Antivirai Efficacy. In­ tracellular Uptake anel Pharmacokinetics of Free anel Liposo­ meencapsulated 2'.3'-clicleoxyinosine. AIDS 1994: 8: 1545-1554.

Makabi-Panzu B, Lessarcl C, Beauchamp D, et al. l'ptake aml Bincling of Liposomal 2',3' Dicleoxycyticline by Raw 264.7 Ce­ lls: A Three-Step Process. J AIDS 1995; 8: 227-235.

Carr A, Vella S, ele Jong Metal. Neveripine Aelded to Ziclovudi­ ne in Nucleosicle Experienced p24 Positive Patients Compa­ reci with Continuecl Ziclovucline Monotherapy. resumo P269- 4th European Conference on Clinical Aspects and Treatment of HIV lnfection. Milão. Março 1994.

Cheeseman S, Havlir D, McLaughlin M, et al. Phase I/II Evalua­tion of Neverapine Alone and in Combination with Zidovudi­ne for Infection with Human Immunodeficiency Virus. J AIDS 1995; 8: 141-150.

Larcler BA. 3'-Azido-3'cleoxytimidine resistence supressed by a mutation conferring human immunodeficiency virus type 1 resistence to monnucleosicle reverse transcriptase inhibi­tors. Antimicrob Agents Chemother. 1992; 36( 12): 2664-2669

Katlama C, The European Lamivudine HIV Working Group. Combination 3TC (Lamivudine)/ZDV (Ziclovudine) Vs. ZDV Monotherapy in ZDV-naive HIV- 1 Positive Patients With CD4 Cells 100-400/ml. Comunicação oral 7.5, 2nd Tnternational Congress on Drug Therapy in HIV Infection. Novembro 1994.

Staszewski S, The European Lamivucline Working Group. Com­ bination 3TC (Lamivucline)/ZDV (Ziclovudine) Vs. ZDV Mo­ notherapy in ZDV Pre-treatecl HIV-1 Positive Patients With CD4 Cells 100-400/ml. Comunicação oral 7.6, 2nd lnternatio­nal Congress on Drug Therapy in HIV lnfection. Novembro 1994. + 3TC Combination Therapy in vivo Supports in vitro Vitoro­gical Observations. Poster 8, 2nd lnternational Congress on Drug Therapy in HIV Infection. Novembro 1994.

Rusconi S, Merril DP, Mazzulli T et ai. Inhibition of Viral Repli­cation in HIV-1 Infected Monocyte/Macrophages by Combi­nation Therapies, resumo 047 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Milão. Mar­ço 1994.

Mazziotti R, Di Toro MT. Tolerance and Efflcacy ofZidovudine and Imerferon-Alpha 2b in HIV Infected Patients, resumo P3 15 - 4th European Conference on Clinicai Aspects and Treat­ mem of HIV Infection. Milão. Março 1994.

Aembrecht C, Mauss S, Manegold C et al. Combination Therapy with Zidovudine and Low dose Alpha-Imerferon in HIV Seropositive Patients; resumo P249 - 4th European Conference on Clinicai Aspects and Treatment of HIV Infection. Milão. Mar­ co 1994.

Krown SE et al. Imerferon-alfa with zidovudine: safety, toleran­ce and clinicai and virologiacal effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syn­drome (AIDS). Ann Int Med 1990; 112: 812-821.

Edlin BR et al. Zidovudine alpha interferon combination thera­py in patients with advanced HIV infection: biphasic respon­se of p24 antigen and quantitative PCR. J Infec Dis. 1992; 165: 743-748.

Barbarini G, Grisorio B, Garavelli G, et al. Zidovudine plus Thymostimulin: a Controlled Study on 200 Asymptomatic HIV+ Subjects. Poster 23, 2nd International Congress on Drug The­rapy in HIV Infection. Novembro 1994.

Maggiolo F, Taras A, Pravettoni MG et al. Preliminary Experien­ce With THF in HIV Positive Patients, resumo P3 11 - 4th Eu­ropean Conference on Clinical Aspects and Treatment of HIV Infection. Milão. Março 1994.

Mauro S, Cariti G, Comito G, et al. AZT + Timopentine Versus AZT in Asymptomatic at High Risk of developing AIDS (AR); resumo P312 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Milão. Marco 1994.

Dinatale F, Ferrara G, Guerci M et al. Zidovudine VS. Zidovudi­ ne- Thymostimulin Association in the Treatment od HIV In­ fected Patients; resumo P313 - 4th European Conference on Clinical Aspects and Treatmem of HIV Infection. Milão. Mar­ ço 1994.

Luke DR, McCreedy BJ, Sarnosky TP et al. Phase !/II study of pentoxyphyline with zidovudine on HIV-1 growth in AIDS patients. lnt J Clin Pharmacol Ther Toxicol 1993; 31(7): 343-350.

Pilsudski R, Aiuti F, Pontesilli O et al, Evaluation of the Effects of Active Immunotherapy with Recombinam GP 160 in Asso­ ciation or not with AZT, in HIV- Infected Individuais with CD4+ Coums > 400 and < 600 cells/mm3; resumo P309 - 4th Euro­ pean Conference on Clinicai Aspects and Treatment of HIV Infection. Milão. Março 1994.

Goldstein G, Conant M, Beall G, et al. Safety and Efficacy of Thymopentin in Zidovudine (AZT)-treated Asymptomatic Subjects with 200-400 Cells/ml: A Double- Blind Placebo-Con­trolled Triai. J AIDS 1994; 8: 279-288.

Meng T-C, fischl M, Cheeseman S, et al. Combination Therapy with Recombinant Human soluble CD4-Immunoglobulin G and Zidovudine in Patients with HIV Infection: A Phase I Stu­ dy. J AIDS 1995; 8: 152-160.

Griffiths P. Cofactors and Mechanisms of Action. Personal com­munication at Aspects of Antiviral Combination Therapy in HIV Management. Vienna. Março 1993.

Gazzard B, Cooper D, Stevens), et al. The Effect of Acyclovir Cotherapy on survival in Advanced HIV Disease. Comunica­ção oral 17.2, 2nd lnternational Congress on Drug Therapy in HIV Infection. Novembro 1994.

Stein D, Graham N, Park L, et al. The Effect of the Imeraction of Acyclovir with Zidovudine on Progression to AIDS and Survi­val, (Analysis of the Data in the Multicenter AIDS Cohort Stu­dy). Ann Int Med 1994; 121: 100-108.

Malley S, Grange J, Hamedi-Sangsari F, et al. Supression of HIV Production in Resting Lymphocytes by Combining Didanosi­ne and Hydroxamate Compounds. Lancet 1994; 343: 1292.

Lori F, Malykh A, Cara A, et al. Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication. Science 1994; 266: 801-805.

Johnson VA. New Developments in Antiretroviral Therapy for HIV Infection, pag: 82-86, in Volberding andJacobson ed. AIDS Clinical Reveiw 1992.

Schooley R. Therapy: new developments. European AIDS Tre­atmem News 1994; 2(5): 7-9.

Chow YK, Hirsch MS, Merril DP et ai. Use of evolutionary limi­ tations od HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361(6413): 650-654.

Richman D. HIV Drug Resistance. Comunicação oral 3.2, 2nd International Congress on Drug Therapy in HIV Infection. Novembro 1994.

Larder B. The Influence of Combination Therapy on HIV-1 Vi­ral Load and Drug Resistance. Comunicação oral 5.1, 2nd In­ternational Congress on Drug Therapy in HIV Infection. No­ vembro 1994.

Yarchoan R, Mitsuya H, Broder S. Challenges in the Therapy of HIV Infection. Immunology Today l993; 14: 303-309.

Havlir D, Richman D. Antiretroviral Therapy. Curent Opinion in Infectious Diseases 1995; 8: 66-73.

Sachs M. Antiretroviral Chemotherapy of Human lmmunodefi­ciency Virus Infections Other Than with Azidothymidine. Arch Intern Med 1992; 152: 485-499.

Johnson VA et ai. Two drug combinations of zidovudine, dida­nosine and recombinam imerferon-alfa. A inhibit replication of zidovudine resistem human immunodeficiency virus type synergistically in vitro. J. Inf Dis. 1991; 164: 646-655.

Ficheiros Adicionais

Publicado

31-03-1995

Como Citar

1.
Teófilo E. Terapêutica anti-retroviral na infecção a VIH (2ª parte). RPMI [Internet]. 31 de Março de 1995 [citado 24 de Abril de 2024];2(1):44-60. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/2345

Edição

Secção

Artigos de Revisão